Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10776 - 10800 of 11626 in total
A light, silvery, metallic element. It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. Its salts are essential in nutrition, being required for the activity of many enzymes, especially those concerned with oxidative phosphorylation. It is a component of both intra- and extracellular fluids and is...
Experimental
Matched Description: … A light, silvery, metallic element. ... It is a component of both intra- and extracellular fluids and is excreted in the urine and feces. …
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability ... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and …
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV ... As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity …
3-Methyl-thiofentanyl is a fentanyl analog and an opioid analgesic that works by inducing central nervous system (CNS) depression.
Experimental
Illicit
Matched Description: … 3-Methyl-thiofentanyl is a [fentanyl] analog and an opioid analgesic that works by inducing central nervous …
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF...
Investigational
Matched Description: … PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular ... Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration …
5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole targets the protein genome polyprotein.
Experimental
Matched Description: … 5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole is a solid. ... These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(7-(6-chloro …
Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin B...
Experimental
Matched Description: … Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil …
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. ... As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … As a lipophilic agent, prinomastat crosses the blood-brain barrier. ... Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. …
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune ... It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction …
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Investigational
Matched Description: … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under …
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease ... VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Investigational
Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Investigational
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus ... The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac ... Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigational
Matched Description: … SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment …
Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Investigational
Matched Description: … Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin …
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Matched Description: … This drug is an analog of fentanyl, a potent opioid. …
Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Investigational
Matched Description: … Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal …
MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).
Investigational
Matched Description: … MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose …
GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Investigational
Matched Description: … GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects …
Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Investigational
Matched Description: … Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants …
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Matched Description: … NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being …
Displaying drugs 10776 - 10800 of 11626 in total